MX2022015580A - 5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8. - Google Patents
5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8.Info
- Publication number
- MX2022015580A MX2022015580A MX2022015580A MX2022015580A MX2022015580A MX 2022015580 A MX2022015580 A MX 2022015580A MX 2022015580 A MX2022015580 A MX 2022015580A MX 2022015580 A MX2022015580 A MX 2022015580A MX 2022015580 A MX2022015580 A MX 2022015580A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- disorders
- inhibitors
- prevention
- management
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- BJSCOTHGFJMOOE-UHFFFAOYSA-N 5-oxopyrrolidine-3-carboxamide Chemical class NC(=O)C1CNC(=O)C1 BJSCOTHGFJMOOE-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 3
- 108091006146 Channels Proteins 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 206010011224 Cough Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040465P | 2020-06-17 | 2020-06-17 | |
| PCT/US2021/037160 WO2021257420A1 (en) | 2020-06-17 | 2021-06-14 | 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015580A true MX2022015580A (es) | 2023-01-24 |
Family
ID=79268285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015580A MX2022015580A (es) | 2020-06-17 | 2021-06-14 | 5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230227405A1 (https=) |
| EP (1) | EP4167993A4 (https=) |
| JP (1) | JP2023530320A (https=) |
| KR (1) | KR20230026405A (https=) |
| CN (1) | CN115697327A (https=) |
| AU (1) | AU2021292062A1 (https=) |
| BR (1) | BR112022024476A2 (https=) |
| CA (1) | CA3180372A1 (https=) |
| MX (1) | MX2022015580A (https=) |
| WO (1) | WO2021257420A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023530319A (ja) | 2020-06-17 | 2023-07-14 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害剤としての２－オキソ－オキサゾリジン－５－カルボキサミド |
| MX2023013147A (es) * | 2021-05-07 | 2023-11-28 | Merck Sharp & Dohme Llc | Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8. |
| EP4334293A1 (en) * | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
| WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| MA64856B1 (fr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| CA3221788A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| JP2024520646A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体 |
| JP2024520643A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| UY40234A (es) | 2022-04-22 | 2023-11-15 | Vertex Pharma | Compuestos heteroarilo para el tratamiento del dolor |
| GEAP202516634A (en) | 2022-04-22 | 2025-02-25 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| JP2025513452A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| IL316433A (en) | 2022-04-25 | 2024-12-01 | Siteone Therapeutics Inc | Bicyclic heterocyclic amide inhibitors of NA v1.8 for the treatment of pain |
| AU2023391870A1 (en) | 2022-12-06 | 2025-06-05 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025122953A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| WO2025160286A1 (en) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| US8202861B2 (en) * | 2003-08-08 | 2012-06-19 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| GB0514017D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| US8710043B2 (en) * | 2011-06-24 | 2014-04-29 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
| WO2014146111A2 (en) * | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Analgesic compounds and methods of use |
| CA2979534A1 (en) * | 2015-03-13 | 2016-09-22 | Abbvie Inc. | (indazol-4-yl)hexahydropyrrolopyrrolones and method of use |
-
2021
- 2021-06-14 BR BR112022024476A patent/BR112022024476A2/pt unknown
- 2021-06-14 MX MX2022015580A patent/MX2022015580A/es unknown
- 2021-06-14 US US18/009,310 patent/US20230227405A1/en active Pending
- 2021-06-14 CA CA3180372A patent/CA3180372A1/en active Pending
- 2021-06-14 WO PCT/US2021/037160 patent/WO2021257420A1/en not_active Ceased
- 2021-06-14 EP EP21826932.2A patent/EP4167993A4/en active Pending
- 2021-06-14 JP JP2022577341A patent/JP2023530320A/ja active Pending
- 2021-06-14 KR KR1020237001357A patent/KR20230026405A/ko active Pending
- 2021-06-14 CN CN202180043604.2A patent/CN115697327A/zh active Pending
- 2021-06-14 AU AU2021292062A patent/AU2021292062A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4167993A1 (en) | 2023-04-26 |
| US20230227405A1 (en) | 2023-07-20 |
| AU2021292062A1 (en) | 2023-01-19 |
| JP2023530320A (ja) | 2023-07-14 |
| CA3180372A1 (en) | 2021-12-23 |
| WO2021257420A1 (en) | 2021-12-23 |
| EP4167993A4 (en) | 2024-07-24 |
| CN115697327A (zh) | 2023-02-03 |
| KR20230026405A (ko) | 2023-02-24 |
| BR112022024476A2 (pt) | 2022-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015581A (es) | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8. | |
| MX2022015580A (es) | 5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8. | |
| MX2022015579A (es) | 2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8. | |
| ZA202102628B (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| CR20230519A (es) | Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 | |
| MX2023013147A (es) | Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8. | |
| EP4595965A3 (en) | Heteroalkyl dihydroquinoline sulfonamide compounds | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| PH12021552134A1 (en) | Pyrazine derivative and application thereof in inhibiting shp2 | |
| GEAP202416515A (en) | Quinoline compounds as inhibitors of kras | |
| PH12018501285A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| MX2021002878A (es) | Inhibidores de cd73 y usos farmaceuticos de los mismos. | |
| MX2025001865A (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| MX2023007150A (es) | Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos. | |
| WO2021242844A8 (en) | Grk2 inhibitors and uses thereof | |
| WO2022051029A3 (en) | Methods for the prevention and treatment of hearing loss | |
| TH2101002482A (th) | 2-อะมิโน-n-เฮเทอโรเอริล-นิโคทินาไมด์ในฐานะที่เป็นตัวยับยั้ง nav1.8 | |
| WO2023122325A3 (en) | Meta anilide compounds and methods for use of the same to treat diseases and disorders | |
| MX2024015496A (es) | Compuestos de pirimidina que contienen boro, composiciones que los contienen, metodos y usos de los mismos | |
| MX2026000100A (es) | Bloqueadores de canales de sodio | |
| GEAP202516658A (en) | Ripk1 inhibitors and methods of use |